Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Hangzhou Jiuyuan Genetic Biopharmaceutical Co (HKSE:02566) Quick Ratio Explanation
The quick ratio is more conservative than the Current Ratio because it excludes inventories from current assets. The ratio derives its name presumably from the fact that assets such as cash and marketable securities are quick sources of cash. Inventories generally take time to be converted into cash, and if they have to be sold quickly, the company may have to accept a lower price than book value of these inventories. As a result, they are justifiably excluded from assets that are ready sources of immediate cash.
In general, low or decreasing quick ratios generally suggest that a company is over-leveraged, struggling to maintain or grow sales, paying bills too quickly or collecting receivables too slowly. On the other hand, a high or increasing quick ratio generally indicates that a company is experiencing solid top-line growth, quickly converting receivables into cash, and easily able to cover its financial obligations. Such companies often have faster inventory turnover and cash conversion cycles.
The higher the quick ratio, the better the company's liquidity position.
Hangzhou Jiuyuan Genetic Biopharmaceutical Co Quick Ratio Related Terms
Hangzhou Jiuyuan Genetic Biopharmaceutical Co Quick Ratio Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Hangzhou Jiuyuan Genetic Biopharmaceutical Co Quick Ratio Chart
Hangzhou Jiuyuan Genetic Biopharmaceutical Co Annual Data
Trend
Dec21
Dec22
Dec23
Dec24
Dec25
Quick Ratio
1.45
1.73
1.96
3.72
4.01
Hangzhou Jiuyuan Genetic Biopharmaceutical Co Semi-Annual Data
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Hangzhou Jiuyuan Genetic Biopharmaceutical Co Quick Ratio vs Biotechnology Industry
Hangzhou Jiuyuan Genetic Biopharmaceutical Co Quick Ratio Calculation
The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. For this reason, the ratio excludes inventories from current assets.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Hangzhou Jiuyuan Genetic Biopharmaceutical Co (HKSE:02566) has a Quick Ratio of 4.01 as of Dec. 2025. Quick ratio is the ratio of current assets less inventory to current liabilities. View historical data on Hangzhou Jiuyuan Genetic Biopharmaceutical Co and its competitors. This is 105% above median its historical median of 1.96. Over the past decade, Hangzhou Jiuyuan Genetic Biopharmaceutical Co's Quick Ratio has ranged from 1.45 to 4.01. According to the industry distribution chart, Hangzhou Jiuyuan Genetic Biopharmaceutical Co ranks #653 out of 1406 companies in the Biotechnology industry, placing it in the top 46.4%.
Is Hangzhou Jiuyuan Genetic Biopharmaceutical Co's Quick Ratio too high?
Hangzhou Jiuyuan Genetic Biopharmaceutical Co's current Quick Ratio of 4.01 is 105% above median its 10-year median of 1.96. Over the past 10 years, this metric has ranged from a low of 1.45 to a high of 4.01. The Biotechnology industry median Quick Ratio is 3.57. Hangzhou Jiuyuan Genetic Biopharmaceutical Co's value of 4.01 is 12.5% above this industry median. Based on the distribution chart, Hangzhou Jiuyuan Genetic Biopharmaceutical Co ranks #653 out of 1406 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Hangzhou Jiuyuan Genetic Biopharmaceutical Co has a GF Score™ of 20/100, reflecting its overall financial health beyond just this single metric.
How does Hangzhou Jiuyuan Genetic Biopharmaceutical Co's Quick Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Hangzhou Jiuyuan Genetic Biopharmaceutical Co ranks #653 out of 1406 companies for Quick Ratio. This puts Hangzhou Jiuyuan Genetic Biopharmaceutical Co in the upper half of its industry. The industry median Quick Ratio is 3.57. Hangzhou Jiuyuan Genetic Biopharmaceutical Co's value of 4.01 is 12.5% above this benchmark. Historically, Hangzhou Jiuyuan Genetic Biopharmaceutical Co's own Quick Ratio has ranged from 1.45 to 4.01 over the past decade. While the company's 10-year median is 1.96 vs. the industry median of 3.57, Hangzhou Jiuyuan Genetic Biopharmaceutical Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Quick Ratio for a Biotechnology company?
The median Quick Ratio among Biotechnology companies is 3.57, based on 1,406 companies in the industry. Companies in the top quartile (top 25%) have a Quick Ratio significantly above this median, while those in the bottom quartile fall well below. However, Quick Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Hangzhou Jiuyuan Genetic Biopharmaceutical Co's current Quick Ratio of 4.01 is 12.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Quick Ratio mean?
A high Quick Ratio can signal that a stock is expensive relative to its fundamentals. Quick ratio is the ratio of current assets less inventory to current liabilities. View historical data on Hangzhou Jiuyuan Genetic Biopharmaceutical Co and its competitors. For the Biotechnology industry, the median Quick Ratio is 3.57 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Hangzhou Jiuyuan Genetic Biopharmaceutical Co's current Quick Ratio is 4.01, which is 105% above median its own 10-year median of 1.96. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Hangzhou Jiuyuan Genetic Biopharmaceutical Co stock overvalued right now?
Hangzhou Jiuyuan Genetic Biopharmaceutical Co (HKSE:02566) has a current Quick Ratio of 4.01. The current Quick Ratio is 4.01, which is 105% above median its 10-year median of 1.96 and 12.5% above the Biotechnology industry median of 3.57. Hangzhou Jiuyuan Genetic Biopharmaceutical Co's overall GF Score™ is 20/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Quick Ratio calculated?
Quick Ratio is calculated from a company's financial statements. For Hangzhou Jiuyuan Genetic Biopharmaceutical Co (HKSE:02566), the current Quick Ratio is 4.01 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Hangzhou Jiuyuan Genetic Biopharmaceutical Co Ltd is a biopharmaceutical company in China. It is engaged in the research & development, manufacturing, and commercialization of biopharmaceutical products and medical devices. The company focuses on four large and fast-growing therapeutic areas: orthopedics, metabolic diseases, oncology, and hematology. Centered around these therapeutic areas, it has built a diversified product portfolio comprising several marketed products, such as Jilifen, Jijufen, Jiouting, Yinuojia, Guyoudao, etc., and has several product candidates under development, such as JY54, JY23, JY47, JY56, JY29-2, etc., targeting various indications. Geographically, the company generates maximum revenue from the Chinese Mainland, and the rest from other countries.
20GF Score
Get the complete analysis for HKSE:02566
Quick Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKSE:02566 has been successfully added to your 
